全文获取类型
收费全文 | 124篇 |
免费 | 20篇 |
专业分类
耳鼻咽喉 | 1篇 |
基础医学 | 3篇 |
内科学 | 20篇 |
皮肤病学 | 41篇 |
神经病学 | 3篇 |
特种医学 | 1篇 |
外科学 | 41篇 |
预防医学 | 4篇 |
眼科学 | 2篇 |
药学 | 1篇 |
肿瘤学 | 27篇 |
出版年
2024年 | 1篇 |
2023年 | 1篇 |
2021年 | 6篇 |
2020年 | 10篇 |
2019年 | 2篇 |
2018年 | 5篇 |
2017年 | 17篇 |
2016年 | 7篇 |
2015年 | 6篇 |
2014年 | 2篇 |
2013年 | 8篇 |
2012年 | 7篇 |
2011年 | 7篇 |
2010年 | 3篇 |
2009年 | 3篇 |
2008年 | 5篇 |
2007年 | 11篇 |
2006年 | 5篇 |
2005年 | 5篇 |
2004年 | 2篇 |
2003年 | 4篇 |
2002年 | 1篇 |
2001年 | 5篇 |
2000年 | 2篇 |
1999年 | 4篇 |
1998年 | 1篇 |
1994年 | 3篇 |
1992年 | 3篇 |
1991年 | 4篇 |
1990年 | 1篇 |
1985年 | 1篇 |
1982年 | 1篇 |
1965年 | 1篇 |
排序方式: 共有144条查询结果,搜索用时 15 毫秒
11.
12.
Timing of Resection of Liver Metastases Synchronous to Colorectal Tumor: Proposal of Prognosis-Based Decisional Model 总被引:2,自引:0,他引:2
Capussotti L Vigano' L Ferrero A Lo Tesoriere R Ribero D Polastri R 《Annals of surgical oncology》2007,14(3):1143-1150
Background Timing of hepatectomy for synchronous metastases of colorectal cancer is still debated. The aim of this retrospective study
was to analyze prognostic factors after synchronous and delayed liver resections to define selection criteria for choosing
timing of hepatectomy.
Methods The study was performed on 127 patients with synchronous metastases undergoing radical hepatectomy. We divided patients according
to the timing of hepatectomy: 70 synchronous (group A) and 57 delayed (group B).
Results Overall survival was similar between the two groups (5-year survival 30.8% vs. 32.0% A vs. B, P = .406). The multivariate analysis evidenced four independent prognostic factors in group A: male sex (P = .04), T4 (P = .0035), more than three metastases (P = .0001), and metastatic infiltration of nearby structures (P < .0001). There were no statistically significant prognostic factors in group B. Patients with more than three metastases
had a significantly worse survival in group A than in group B (3-year survival, 15.0% vs. 34.3%, P = .007); similarly, borderline significant difference was encountered in patients with T4 primary tumor (3-year survival,
16.7% vs. 60%, P = .064)
Conclusions Patients with liver metastases synchronous with colorectal cancer with T4 primary tumor, metastasis infiltration of neighboring
structures, and especially with more than three metastases should receive neoadjuvant chemotherapy before liver resection. 相似文献
13.
Ughetto Stefano Migliore Cristina Pietrantonio Filippo Apicella Maria Petrelli Annalisa DErrico Laura Durando Stefania Moya-Rull Daniel Bellomo Sara E. Rizzolio Sabrina Capela Tania Ribisi Salvatore Degiuli Maurizio Reddavid Rossella Rapa Ida Fumagalli Uberto De Pascale Stefano Ribero Dario Baronchelli Carla Sgroi Giovanni Rausa Emanuele Baiocchi Gian Luca Molfino Sarah Manenti Stefania Bencivenga Maria Sacco Michele Castelli Claudia Siena Salvatore Sartore-Bianchi Andrea Tosi Federica Morano Federica Raimondi Alessandra Prisciandaro Michele Gloghini Annunziata Marsoni Silvia Sottile Antonino Sarotto Ivana Sapino Anna Marchi Caterina Cassoni Paola Guarrera Simonetta Corso Simona Giordano Silvia 《Gastric cancer》2021,24(4):897-912
Gastric Cancer - Trastuzumab is the only approved targeted therapy in patients with HER2-amplified metastatic gastric cancer (GC). Regrettably, in clinical practice, only a fraction of them... 相似文献
14.
15.
Sharon M Weber Dario Ribero Eileen M O=Reilly Norihiro Kokudo Masaru Miyazaki Timothy M Pawlik 《HPB : the official journal of the International Hepato Pancreato Biliary Association》2015,17(8):669-680
An American Hepato-Pancreato-Biliary Association (AHPBA)-sponsored consensus meeting of expert panellists met on 15 January 2014 to review current evidence on the management of intrahepatic cholangiocarcinoma (ICC) in order to establish practice guidelines and to agree on consensus statements. The treatment of ICC requires a coordinated, multidisciplinary approach to optimize survival. Biopsy is not necessary if the surgeon suspects ICC and is planning curative resection, although biopsy should be obtained before systemic or locoregional therapies are initiated. Assessment of resectability is best accomplished using cross-sectional imaging [computed tomography (CT) or magnetic resonance imaging (MRI)], but the role of positron emission tomography (PET) is unclear. Resectability in ICC is defined by the ability to completely remove the disease while leaving an adequate liver remnant. Extrahepatic disease, multiple bilobar or multicentric tumours, and lymph node metastases beyond the primary echelon are contraindications to resection. Regional lymphadenectomy should be considered a standard part of surgical therapy. In patients with high-risk features, the routine use of diagnostic laparoscopy is recommended. The preoperative diagnosis of combined hepatocellular carcinoma and cholangiocarcinoma (cHCC–CC) by imaging studies is extremely difficult. Surgical resection remains the mainstay of treatment, but survival is worse than in HCC alone. There are no adequately powered, randomized Phase III trials that can provide definitive recommendations for adjuvant therapy for ICC. Patients with high-risk features (lymphovascular invasion, multicentricity or satellitosis, large tumours) should be encouraged to enrol in clinical trials and to consider adjuvant therapy. Cisplatin plus gemcitabine represents the standard-of-care, front-line systemic therapy for metastatic ICC. Genomic analyses of biliary cancers support the development of targeted therapeutic interventions. 相似文献
16.
Authors' reply to: High naevus counts confer a favourable prognosis in patients with melanoma 下载免费PDF全文
17.
Gelatti U Covolo L Franceschini M Pirali F Tagger A Ribero ML Trevisi P Martelli C Nardi G Donato F;Brescia HCC Study Group 《Journal of hepatology》2005,42(4):528-534
BACKGROUND/AIMS: The role of coffee in the development of hepatocellular carcinoma (HCC) is debated. The aim of this study was to investigate the role of coffee in HCC, taking the main risk factors into account. METHODS: A hospital-based case-control study was conducted in an area of northern Italy. We recruited 250 HCC cases and 500 controls hospitalized for any reasons other than neoplasms, and liver and alcohol-related diseases. Subjects were interviewed on their lifetime history of coffee consumption using a standardized questionnaire. RESULTS: Coffee consumption in the decade before the interview was associated with a decreasing risk of HCC with a clear dose-effect relation. With respect to non-drinking subjects, the odds ratios (ORs) were: 0.8, (95% CI 0.4-1.3) for 1-2 cups/day, 0.4 (95% CI 0.2-0.8) for 3-4 cups/day and 0.3 (95% CI 0.1-0.7) for 5 or more cups/day. The ORs for HCC decreased for drinking >2, compared to 0-2 cups/day of coffee, for an alcohol intake >80 g/day (OR from 5.7 to 3.3), for presence of hepatitis B virus infection (OR from 16.4 to 7.3) or hepatitis C virus infection (OR from 38.2 to 9.0). CONCLUSIONS: Coffee drinking was inversely associated with HCC regardless of its aetiology. 相似文献
18.
Hepatitis C virus infection and chronic liver disease in children with leukemia in long-term remission 总被引:2,自引:0,他引:2
Locasciulli A; Gornati G; Tagger A; Ribero ML; Cavalletto D; Cavalletto L; Masera G; Shulman HM; Portmann B; Alberti A 《Blood》1991,78(6):1619-1622
Antibody to the recently identified hepatitis C virus (HCV) was investigated in sera of 50 leukemic children who had chronic liver disease (CLD), observed for 1 to 12.6 years after therapy withdrawal. All patients were tested for anti-HCV at regular intervals: Ortho- enzyme-linked immunosorbent assay (ELISA) test was performed in all cases. Reactive sera were also tested by recombinant immunoblotting assay to define the specificity of the results obtained by ELISA. Twelve cases (24%) were persistently positive (group A), 11 (22%) were transiently anti-HCV+ positive (group B), and 27 (54%) were negative. Mean SGPT peak during follow-up was significantly higher in group A (P = .014, A v B and P less than .00001, A v C). SGPT normalized off- therapy in 1 of 12 cases (group A), 10 of 11 (group B), and 19 of 27 (group C) (P = .0004, A v B and P = .012, A v C). Accordingly, liver histology, available in 37 patients, showed signs of chronic hepatitis in all patients in group A while most patients in group B and C had less severe liver lesions. These results indicate that HCV plays a significant role in the etiology of chronic hepatitis in leukemic patients and that persistent anti-HCV activity correlates with a more severe CLD, which could jeopardize the final prognosis of children cured of leukemia. 相似文献
19.
Federico Tremolada Carla Casarin Alfredo Alberti Claudio Drago Alessandro Tagger Maria Luisa Ribero Giuseppe Realdi 《Journal of hepatology》1992,16(3)
One hundred and thirty-five patients who developed non-A, non-B post-transfusion hepatitis mostly after cardiac surgery, were followed for a mean (±S.D.) of 90±41 months (range: 13–180) to evaluate clinical and histological outcome.Thirty-one cases resolved within 12 months, while 104 (77%) progressed to chronicity. Twenty-one of 65 (32%) biopsied patients developed cirrhosis at the end of the follow-up, and one further progressed to hepatocellular carcinoma. One patient had a complete histological remission (1%). The remaining cases had chronic active (37%), chronic persistent (27%) or chronic lobular hepatitis (3%). About half of the cases with cirrhosis developed portal hypertension, and three of these died due to esophageal varices hemorrhage, one due to liver failure, and one due to hepatocellular carcinoma. Out of 26 patients with the initial histologic diagnosis of chronic hepatitis that were rebiopsied during follow-up, 13 (50%) progressed to cirrhosis. These patients were significantly older than patients who did not develop cirrhosis (mean age 57 and 45 years respectively; p<0.01).During acute hepatitis anti-HCV was positive in all but one of the 114 patients tested. Percentages were similar for patients who recovered (95%) and those who developed chronic hepatitis (100%). However, during follow-up, 71% of the 1st generation and 21% of the 2nd generation ELISA test patients with acute resolved hepatitis became anti-HCV negative, while the same figures in chronic cases were only 8.5% (p<0.0001) and 1.4% (p=0.012). This suggests a correlation between anti-HCV antibody activity, hepatitis C virus replication, and the development of chronic liver disease. 相似文献
20.
Giovanna Fattovich Maria Lisa Ribero Susanna Favarato Franco Azzario Francesco Donato Giuliano Giustina Michele Fasola Maurizio Pantalena Giuseppe Portera Alessandro Tagger 《Liver international》1998,18(5):360-365
Abstract: Aims/Background: The clinical significance of GB virus-C/hepatitis G virus (GBV-C/HGV) infection in chronic hepatitis B is not well known and its role in the outcome of liver disease was investigated. Methods: HGV-RNA and antibody to HGV (anti-E2) were studied in 125 patients with chronic hepatitis B (41 with multiple hepatitis virus exposure), 82 asymptomatic HBsAg carriers and 103 healthy adults. Results: In chronic hepatitis B, HGV-RNA was more frequent in patients with HDV infection and/or anti-HCV positivity than in those without (29% vs 6%, p<0.0001), mainly in drug addicts (38%). At diagnosis the overall prevalence of any marker (HGV-RNA plus anti-E2) was similar in chronic hepatitis due to HBV alone (17%), in HBsAg carriers (16%) and in healthy adults (17%) and increased to 58% in those exposed to HDV and/or HCV. During 1–11 years of follow-up, HGV infection persisted in 70% of patients with chronic hepatitis B. About 40% of HGV persistently coinfected patients underwent sustained biochemical remission, whereas continuing disease activity was observed in 80% of patients who cleared HGV-RNA. Conclusions: In chronic HBV infection the rate of exposure to HGV is similar to that in healthy adults, except for high risk patients. Long lasting HGV coinfection or anti-E2 seroconversion did not modify the course of chronic hepatitis B. 相似文献